Alnylam Pharmaceuticals Target RAISED and 1 Stock Analysis to Notice Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) price target was increased by Needham after its positive ALN-TTR-02 trial results. Shares have a Buy rating.

Don’t Miss: Will the New iPhone SMASH Records?

Marriott International, Inc. (NYSE:MAR) reported in-line adjusted EPS for Q2 causing Argus to predict that the company’s earnings will surpass expectations going forward. The firm believes the stock will do well through the long-term, and it keeps a Buy rating on the shares.

Don’t Miss: Why Are Ford Sales SLUMPING?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business